Biogen (BIIB) Competitors

Biogen logo
$249.59 +2.46 (+1.00%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$250.00 +0.41 (+0.17%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BIIB vs. AMGN, GILD, IONS, MRNA, and PRTA

Should you buy Biogen stock or one of its competitors? Biogen's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), and Prothena (PRTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biogen compare to Amgen?

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Amgen has a net margin of 24.14% compared to Biogen's net margin of 3.37%. Amgen's return on equity of 114.99% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen24.14% 114.99% 13.47%
Biogen 3.37%9.38%5.69%

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B6.41$7.71B$17.2425.26
Biogen$9.89B3.73$1.29B$2.34106.66

Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Biogen has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Amgen presently has a consensus price target of $428.62, suggesting a potential downside of 1.58%. Biogen has a consensus price target of $255.45, suggesting a potential upside of 2.35%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
3 Sell rating(s)
18 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.30
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67

In the previous week, Biogen had 23 more articles in the media than Amgen. MarketBeat recorded 51 mentions for Biogen and 28 mentions for Amgen. Biogen's average media sentiment score of 0.75 beat Amgen's score of 0.63 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
13 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Biogen
24 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive

76.5% of Amgen shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amgen beats Biogen on 9 of the 16 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.73$1.29B$2.34106.66
Gilead Sciences$29.44B7.01$8.51B-$3.16N/A

87.9% of Biogen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biogen currently has a consensus price target of $255.45, indicating a potential upside of 2.35%. Gilead Sciences has a consensus price target of $171.63, indicating a potential upside of 3.19%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.79

Biogen has a net margin of 3.37% compared to Gilead Sciences' net margin of -12.47%. Biogen's return on equity of 9.38% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Gilead Sciences -12.47%-1.85%-0.61%

In the previous week, Gilead Sciences had 2 more articles in the media than Biogen. MarketBeat recorded 53 mentions for Gilead Sciences and 51 mentions for Biogen. Gilead Sciences' average media sentiment score of 0.77 beat Biogen's score of 0.75 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
24 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive
Gilead Sciences
24 Very Positive mention(s)
10 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Gilead Sciences beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Biogen has a net margin of 3.37% compared to Ionis Pharmaceuticals' net margin of -56.98%. Biogen's return on equity of 9.38% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Ionis Pharmaceuticals -56.98%-120.62%-16.99%

Biogen currently has a consensus price target of $255.45, indicating a potential upside of 2.35%. Ionis Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 182.14%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78

Biogen has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

In the previous week, Biogen had 26 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 51 mentions for Biogen and 25 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.75 beat Ionis Pharmaceuticals' score of -0.02 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
24 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive
Ionis Pharmaceuticals
4 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.73$1.29B$2.34106.66
Ionis Pharmaceuticals$944M4.69-$381.39M-$3.32N/A

Summary

Biogen beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Biogen compare to Moderna?

Biogen (NASDAQ:BIIB) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Biogen has a net margin of 3.37% compared to Moderna's net margin of -110.46%. Biogen's return on equity of 9.38% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Moderna -110.46%-25.79%-15.85%

In the previous week, Biogen had 16 more articles in the media than Moderna. MarketBeat recorded 51 mentions for Biogen and 35 mentions for Moderna. Biogen's average media sentiment score of 0.75 beat Moderna's score of 0.23 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
24 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive
Moderna
9 Very Positive mention(s)
7 Positive mention(s)
10 Neutral mention(s)
5 Negative mention(s)
1 Very Negative mention(s)
Neutral

Biogen presently has a consensus target price of $255.45, suggesting a potential upside of 2.35%. Moderna has a consensus target price of $120.25, suggesting a potential downside of 38.07%. Given Biogen's stronger consensus rating and higher probable upside, research analysts clearly believe Biogen is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Moderna
4 Sell rating(s)
15 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.08

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.73$1.29B$2.34106.66
Moderna$2.52B31.18-$2.82B-$7.10N/A

Biogen has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Moderna has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

87.9% of Biogen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Biogen beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Biogen compare to Prothena?

Prothena (NASDAQ:PRTA) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

97.1% of Prothena shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biogen has a net margin of 3.37% compared to Prothena's net margin of -45.44%. Biogen's return on equity of 9.38% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Prothena-45.44% -9.98% -9.08%
Biogen 3.37%9.38%5.69%

In the previous week, Biogen had 48 more articles in the media than Prothena. MarketBeat recorded 51 mentions for Biogen and 3 mentions for Prothena. Prothena's average media sentiment score of 1.94 beat Biogen's score of 0.75 indicating that Prothena is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prothena
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Biogen
24 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive

Prothena has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, Biogen has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Biogen has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$9.68M43.61-$244.09M-$0.48N/A
Biogen$9.89B3.73$1.29B$2.34106.66

Prothena currently has a consensus target price of $20.00, suggesting a potential upside of 143.31%. Biogen has a consensus target price of $255.45, suggesting a potential upside of 2.35%. Given Prothena's higher possible upside, equities analysts plainly believe Prothena is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Biogen beats Prothena on 10 of the 15 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIIB vs. The Competition

MetricBiogenBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$36.89B$3.92B$7.44B$10.86B
Dividend YieldN/A3.78%2.51%4.60%
P/E Ratio106.6623.0732.5628.67
Price / Sales3.7314.727.765.16
Price / Cash11.0321.9220.2520.77
Price / Book1.954.124.343.51
Net Income$1.29B-$24.08M$3.51B$394.12M
7 Day Performance-1.50%-9.85%-8.07%-8.97%
1 Month Performance-1.67%-12.77%-10.29%-11.61%
1 Year Performance42.38%-7.99%-4.70%-11.21%

Biogen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIIB
Biogen
2.904 of 5 stars
$249.59
+1.0%
$255.45
+2.3%
+42.4%$36.89B$9.89B106.667,500
AMGN
Amgen
3.584 of 5 stars
$462.32
-0.7%
$425.69
-7.9%
+29.0%$250.07B$38.90B26.8231,500
GILD
Gilead Sciences
3.198 of 5 stars
$167.58
-0.3%
$171.63
+2.4%
+31.3%$207.86B$30.99BN/A17,000
IONS
Ionis Pharmaceuticals
2.8718 of 5 stars
$28.01
-3.6%
$75.71
+170.3%
-65.1%$4.66B$960.09MN/A1,402
MRNA
Moderna
1.3335 of 5 stars
$215.27
-3.6%
$113.75
-47.2%
+718.6%$87.10B$2.52BN/A4,700

Related Companies and Tools


This page (NASDAQ:BIIB) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners